Objective:

To evaluate the efficacy and safety of OCU410, a novel modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).

Key Findings:

• 31% reduction in GA lesion growth at optimal dose compared to control.
• 27% slower rate of ellipsoid zone loss, indicating photoreceptor preservation.
• 55% of patients achieved at least a 30% reduction in lesion size.
• No serious adverse events reported, indicating a favorable safety profile.

Interpretation:

OCU410 shows promise as a more effective and less burdensome treatment option for GA compared to existing therapies, which require frequent injections.

Limitations:

• Small sample size of 51 patients.
• Results based on a single phase 2 trial.

Conclusion:

OCU410 may represent a significant advancement in GA treatment, with plans for a phase 3 trial to further evaluate its efficacy and safety.